Atopic Dermatitis’ Treatment Patterns in Latin America: A Systematic Literature Review

Speaker(s)

Criado PR1, Ianhez M2, Lorenzini D3, Seugling FR4, Pinheiro MRT4, Padula AC5, Amaral LM6, Encinas GA7, Santos HW4, Gaspari C8, Saviolli Piton L9
1Centro Universitário FMABC, Santo André, São Paulo, Brazil, 2Universidade Federal de Goiás, Goiânia, Brazil, 3Irmandade Santa Casa de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil, 4Pfizer, São Paulo, São Paulo, Brazil, 5ORIGIN Health, São Paulo, São Paulo, Brazil, 6ORIGIN Health, Rio de Janeiro, RJ, Brazil, 7Pfizer S.A. de C.V, Mexico City, EM, Mexico, 8Pfizer, São Paulo, Brazil, 9Pfizer Brasil LTDA, São Paulo, São Paulo, Brazil

Presentation Documents

OBJECTIVES: Atopic dermatitis (AD) is a chronic inflammatory disease with a prevalence of about 2.68% worldwide. The treatments to manage the disease are diverse and barriers, such as cost and access to novel technologies are relevant, especially in developing countries. Therefore, the objective of this study was to conduct a systematic literature review (SLR) to evaluate treatment patterns in adults and adolescents with moderate to severe AD in Latin America.

METHODS: A SLR including only observational studies was conducted, and included studies with adult and adolescent population with moderate-severe AD. The electronic search was conducted by two reviewers exploring publications until July 2022 in The Cochrane Library, MEDLINE, LILACS, and Embase database. The variables of interest were treatment profile, treatment failure, time to treatment failure, and subsequent therapies. The risk of bias was assessed using the Joanna Briggs Institute (JBI) Critical Appraisal Tools.

RESULTS: A total of 1,444 studies were returned, and 10 studies fulfilled eligibility criteria, considering studies reporting data regardless of disease severity. In the included studies, the therapeutic strategies varied from 12.2 to 91.9% for topical treatment, 71.3% as systemic corticosteroids, 55.4 to 63.3% for oral antihistamines and 35% for phototherapy. For individuals with moderate to severe disease, topical treatments are also used (ranging from 42.5 to 100%), in addition to systemic corticosteroids (100%), oral antihistamines (ranging from 86 to 86.3%), and cyclosporine (ranging from 22.5 to 75%) as most frequently reported as therapeutic strategies.

CONCLUSIONS: This SLR demonstrated that, in Latin America, topical therapies are broadly used as the first choice for AD treatment and systemic corticosteroids are usually the choice for individuals presenting moderate to severe disease. The absence of a clear treatment algorithm is noted, which may indicate a lack of knowledge or access to new therapies for treating moderate to severe AD.

Code

HSD45

Disease

Mental Health (including addition), Pediatrics, Sensory System Disorders (Ear, Eye, Dental, Skin)